Semaglutide (GLP-1) Research Overview: From Receptor Pharmacology to Published Trials
Unlike most research peptides, semaglutide arrives with an enormous published evidence base: it is among the most studied peptides ever synthesized. That makes it a well-characterized reference compound for metabolic research — and makes accuracy about what the literature shows easy to check.
The molecule
Semaglutide is a 31-amino-acid analog of human GLP-1 (glucagon-like peptide-1) with three deliberate modifications: an Aib substitution at position 8 that blocks DPP-4 degradation, a C18 fatty-diacid chain that binds albumin, and a spacer that optimizes that binding. Together these stretch GLP-1's natural half-life of minutes into roughly a week — the property that made once-weekly dosing possible in the clinical programs.
Receptor pharmacology
Semaglutide is a selective agonist of the GLP-1 receptor, a class-B GPCR expressed in pancreatic beta cells, hypothalamic and hindbrain neurons, and other tissues. Receptor activation raises cAMP, potentiates glucose-dependent insulin secretion, slows gastric emptying and acts centrally on appetite circuits. Its selectivity — one receptor, no GIP or glucagon activity — is what makes it the natural comparator when studying the newer dual and triple agonists.
The published clinical evidence
Two landmark programs define the human literature: the SUSTAIN trials in type 2 diabetes, and the STEP program in obesity, where STEP 1 reported a mean ~15% body-weight reduction over 68 weeks versus ~2.4% with placebo. Subsequent published work (SELECT) demonstrated cardiovascular outcome benefits in non-diabetic participants with obesity. These results are why GLP-1 biology is currently the most active area of metabolic research.
Current research directions
- Receptor signaling bias and desensitization in cell models
- Central appetite circuitry mapping in rodent models
- Comparative pharmacology against dual/triple incretin agonists
- Muscle-preservation co-therapies during weight loss (an active trial area)
Laboratory notes
Research-grade semaglutide is supplied lyophilized and follows standard handling: reconstitute gently in bacteriostatic water, refrigerate, protect from light. Its fatty-acid chain makes it more surface-active than small peptides — foaming from shaking is a real degradation risk. Verify each batch against its COA; molecular weight is ~4114 Da by mass spec.
We stock independently tested GLP-1 semaglutide (10mg vials), alongside cagrilintide for amylin-pathway comparison work. For research use only — not for human or veterinary use.